

**Clinical trial results:****A Multicenter, Randomized, Multiple-dose Phase 3 Study to Evaluate the Noninferiority of Romosozumab at a 90 mg/mL Concentration Compared With a 70 mg/mL Concentration in Postmenopausal Women With Osteoporosis****Summary**

EudraCT number	2013-000434-35
Trial protocol	PL CZ
Global end of trial date	08 December 2014

**Results information**

Result version number	v1 (current)
This version publication date	17 July 2016
First version publication date	17 July 2016

**Trial information****Trial identification**

Sponsor protocol code	20120156
-----------------------	----------

**Additional study identifiers**

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02016716
WHO universal trial number (UTN)	-

Notes:

**Sponsors**

Sponsor organisation name	Amgen, Inc.
Sponsor organisation address	One Amgen Center Drive, Thousand Oaks, CA, United States, 91320
Public contact	IHQ-Medical Info - Clinical Trials, Amgen (Europe) GmbH, MedinfoInternational@amgen.com
Scientific contact	IHQ-Medical Info - Clinical Trials, Amgen (Europe) GmbH, MedinfoInternational@amgen.com

Notes:

**Paediatric regulatory details**

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	08 December 2014
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	08 December 2014
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

To evaluate the non-inferiority of a 6-month treatment with 210 mg romosozumab administered every month (QM) using a 90 mg/mL concentration compared with 210 mg romosozumab QM using a 70 mg/mL concentration on percent change from baseline in bone mineral density (BMD) at the lumbar spine as assessed by dual-energy x-ray absorptiometry (DXA) in postmenopausal women with osteoporosis.

Protection of trial subjects:

This study was conducted in accordance with International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) and applicable country regulations/guidelines.

The protocol, informed consent form (ICF), other written subject information were submitted to the applicable Independent Ethics Committee (IEC) or Institutional Review Board (IRB) for written approval, which was received by Amgen before recruitment of subjects into the study and shipment of Amgen investigational product.

All subjects provided written informed consent after the aims, methods, and potential risks of the study were adequately explained. Informed consent was obtained before any protocol-specific screening procedures or any investigational products were administered.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	03 December 2013
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Poland: 250
Country: Number of subjects enrolled	Czech Republic: 15
Country: Number of subjects enrolled	United States: 29
Worldwide total number of subjects	294
EEA total number of subjects	265

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0

Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	115
From 65 to 84 years	175
85 years and over	4

## Subject disposition

### Recruitment

Recruitment details:

This study was conducted at 11 centers: 7 in Poland, 2 in the Czech Republic, and 2 in the United States. The First subject enrolled on 03 December 2013 and the last subject enrolled on 07 March 2014.

### Pre-assignment

Screening details:

After signing informed consent subjects entered a screening period to complete eligibility assessments. Eligible subjects were randomized in a 22:5:22:5 ratio to

- romosozumab 90 mg/mL
- placebo 90 mg/mL
- romosozumab 70 mg/mL
- placebo 70 mg/mL

For efficacy analyses the 2 placebo groups were combined, for safety the data are reported separately.

### Period 1

Period 1 title	Overall study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Blinding implementation details:

Randomization was double-blind within the concentrations (romosozumab 90 mg/mL and placebo 90 mg/mL; romosozumab 70 mg/mL and placebo 70 mg/mL).

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Placebo

Arm description:

Participants received matching placebo (either administered as 2 subcutaneous (SC) injections of 1.17 mL or 3 SC injections of 1.0 mL) every month for 6 months.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Administered by subcutaneous injection once a month

<b>Arm title</b>	Romosozumab 70 mg/mL
------------------	----------------------

Arm description:

Participants received 210 mg romosozumab monthly, administered as 3 subcutaneous 1 mL injections of a 70 mg/mL solution, for 6 months.

Arm type	Experimental
Investigational medicinal product name	Romosozumab
Investigational medicinal product code	AMG 785
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Administered as 3 SC injections of a 70 mg/mL concentration in a 1.0 mL glass prefilled syringe.

<b>Arm title</b>	Romosozumab 90 mg/mL
------------------	----------------------

Arm description:

Participants received 210 mg romosozumab monthly, administered as 2 subcutaneous 1.17 mL injections of a 90 mg/mL solution, for 6 months.

Arm type	Experimental
Investigational medicinal product name	Romosozumab
Investigational medicinal product code	AMG 785
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Administered as 2 SC injections of a 90 mg/mL concentration in a 1.17 mL crystal zenith resin prefilled syringe.

<b>Number of subjects in period 1</b>	Placebo	Romosozumab 70 mg/mL	Romosozumab 90 mg/mL
Started	53	118	123
Completed	47	110	117
Not completed	6	8	6
Consent withdrawn by subject	5	5	5
Lost to follow-up	1	2	1
Protocol-specified criteria	-	1	-

## Baseline characteristics

### Reporting groups

Reporting group title	Placebo
Reporting group description: Participants received matching placebo (either administered as 2 subcutaneous (SC) injections of 1.17 mL or 3 SC injections of 1.0 mL) every month for 6 months.	
Reporting group title	Romosozumab 70 mg/mL
Reporting group description: Participants received 210 mg romosozumab monthly, administered as 3 subcutaneous 1 mL injections of a 70 mg/mL solution, for 6 months.	
Reporting group title	Romosozumab 90 mg/mL
Reporting group description: Participants received 210 mg romosozumab monthly, administered as 2 subcutaneous 1.17 mL injections of a 90 mg/mL solution, for 6 months.	

Reporting group values	Placebo	Romosozumab 70 mg/mL	Romosozumab 90 mg/mL
Number of subjects	53	118	123
Age categorical			
Units: Subjects			
< 65 years	23	46	46
≥ 65 years	30	72	77
Age continuous			
Units: years			
arithmetic mean	68.4	67.4	67.7
standard deviation	± 8	± 7.1	± 7.6
Gender categorical			
Units: Subjects			
Female	53	118	123
Male	0	0	0
Race			
Units: Subjects			
Asian	0	2	0
Black (or African American)	0	1	0
White	53	115	123
Lumbar Spine Bone Mineral Density (BMD) T-score			
The T-score is the bone mineral density (BMD) at the site when compared to that of a healthy thirty-year-old. Normal is a T-score of -1.0 or higher; Osteopenia is defined as between -1.0 and -2.5; Osteoporosis is defined as -2.5 or lower, meaning a bone density that is two and a half standard deviations below the mean of a thirty-year-old man/woman.			
Units: T-score			
arithmetic mean	-2.842	-2.965	-3.029
standard deviation	± 1.033	± 0.96	± 0.687
Total Hip BMD T-score			
Units: T-score			
arithmetic mean	-2.057	-1.819	-1.828
standard deviation	± 0.634	± 0.673	± 0.649
Femoral Neck BMD T-score			
Units: T-score			
arithmetic mean	-2.304	-2.139	-2.018

standard deviation	± 0.517	± 0.611	± 0.593
Serum Procollagen Type 1 N-telopeptide (P1NP) Units: µg/L			
median	49	53	50
inter-quartile range (Q1-Q3)	38 to 61	40 to 61	40 to 64
Serum Type 1 Collagen C-telopeptide (CTX) Units: ng/L			
median	426.5	440	402
inter-quartile range (Q1-Q3)	296.5 to 560.5	288 to 613	299 to 530

<b>Reporting group values</b>	Total		
Number of subjects	294		
Age categorical Units: Subjects			
< 65 years	115		
≥ 65 years	179		
Age continuous Units: years			
arithmetic mean			
standard deviation	-		
Gender categorical Units: Subjects			
Female	294		
Male	0		
Race Units: Subjects			
Asian	2		
Black (or African American)	1		
White	291		
Lumbar Spine Bone Mineral Density (BMD) T-score			
The T-score is the bone mineral density (BMD) at the site when compared to that of a healthy thirty-year-old. Normal is a T-score of -1.0 or higher; Osteopenia is defined as between -1.0 and -2.5; Osteoporosis is defined as -2.5 or lower, meaning a bone density that is two and a half standard deviations below the mean of a thirty-year-old man/woman.			
Units: T-score			
arithmetic mean			
standard deviation	-		
Total Hip BMD T-score Units: T-score			
arithmetic mean			
standard deviation	-		
Femoral Neck BMD T-score Units: T-score			
arithmetic mean			
standard deviation	-		
Serum Procollagen Type 1 N-telopeptide (P1NP) Units: µg/L			
median			
inter-quartile range (Q1-Q3)	-		
Serum Type 1 Collagen C-telopeptide			

(CTX)  
Units: ng/L  
median  
inter-quartile range (Q1-Q3)

-		
---	--	--

## End points

### End points reporting groups

Reporting group title	Placebo
Reporting group description: Participants received matching placebo (either administered as 2 subcutaneous (SC) injections of 1.17 mL or 3 SC injections of 1.0 mL) every month for 6 months.	
Reporting group title	Romosozumab 70 mg/mL
Reporting group description: Participants received 210 mg romosozumab monthly, administered as 3 subcutaneous 1 mL injections of a 70 mg/mL solution, for 6 months.	
Reporting group title	Romosozumab 90 mg/mL
Reporting group description: Participants received 210 mg romosozumab monthly, administered as 2 subcutaneous 1.17 mL injections of a 90 mg/mL solution, for 6 months.	

### Primary: Percent Change From Baseline in Bone Mineral Density (BMD) at the Lumbar Spine

End point title	Percent Change From Baseline in Bone Mineral Density (BMD) at the Lumbar Spine
End point description: Bone mineral density was measured by dual-energy X-ray absorptiometry (DXA).	
End point type	Primary
End point timeframe: Baseline and month 6	

End point values	Placebo	Romosozumab 70 mg/mL	Romosozumab 90 mg/mL	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	46 <sup>[1]</sup>	110 <sup>[2]</sup>	117 <sup>[3]</sup>	
Units: percent change				
least squares mean (confidence interval 95%)	0.8 (-0.4 to 2.1)	9.6 (8.8 to 10.4)	9.2 (8.4 to 10)	

Notes:

- [1] - Subjects with values at baseline and at month 6
- [2] - Subjects with values at baseline and at month 6
- [3] - Subjects with values at baseline and at month 6

### Statistical analyses

Statistical analysis title	Non-inferiority Analysis
Statistical analysis description: For the evaluation of the non-inferiority hypothesis, the least squares mean of the treatment difference for romosozumab treatment groups only (romosozumab 90 mg/mL - romosozumab 70 mg/mL) and the corresponding lower 1-sided 97.5% CI was estimated using an ANCOVA model adjusting for treatment, and baseline lumbar spine BMD T-score.	
Comparison groups	Romosozumab 70 mg/mL v Romosozumab 90 mg/mL

Number of subjects included in analysis	227
Analysis specification	Pre-specified
Analysis type	non-inferiority <sup>[4]</sup>
Parameter estimate	Least Squares Mean Difference
Point estimate	-0.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.5
upper limit	0.7

Notes:

[4] - The primary hypothesis was that the mean percent change from baseline in lumbar spine BMD at month 6 in subjects receiving romosozumab 210 mg QM using the 90 mg/mL concentration would not be inferior to that in subjects receiving romosozumab 210 mg QM using the 70 mg/mL concentration using a margin of -2.0%.

### Secondary: Percent Change From Baseline in Total Hip BMD

End point title	Percent Change From Baseline in Total Hip BMD
End point description:	
Total hip BMD was measured using DXA. Analysis was based on ANCOVA model adjusting for treatment, and baseline total hip BMD T score.	
End point type	Secondary
End point timeframe:	
Baseline and month 6	

End point values	Placebo	Romosozumab 70 mg/mL	Romosozumab 90 mg/mL	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	46 <sup>[5]</sup>	110 <sup>[6]</sup>	116 <sup>[7]</sup>	
Units: percent change				
least squares mean (confidence interval 95%)	0 (-0.9 to 0.8)	3.9 (3.4 to 4.4)	3.4 (2.9 to 4)	

Notes:

[5] - Subjects with values at baseline and at month 6

[6] - Subjects with values at baseline and at month 6

[7] - Subjects with values at baseline and at month 6

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percent Change From Baseline in Femoral Neck BMD

End point title	Percent Change From Baseline in Femoral Neck BMD
End point description:	
Femoral neck BMD was measured using DXA. The analysis was based on ANCOVA model adjusting for treatment, and baseline femoral neck BMD T score.	
End point type	Secondary
End point timeframe:	
Baseline and month 6	

<b>End point values</b>	Placebo	Romosozumab 70 mg/mL	Romosozumab 90 mg/mL	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	46 <sup>[8]</sup>	110 <sup>[9]</sup>	116 <sup>[10]</sup>	
Units: percent change				
least squares mean (confidence interval 95%)	-0.5 (-1.5 to 0.5)	3.1 (2.5 to 3.8)	2.6 (2 to 3.3)	

Notes:

[8] - Subjects with values at baseline and month 6

[9] - Subjects with values at baseline and month 6

[10] - Subjects with values at baseline and month 6

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percent Change From Baseline in N-Terminal Propeptide Type 1 Procollagen (P1NP)

End point title	Percent Change From Baseline in N-Terminal Propeptide Type 1 Procollagen (P1NP)
-----------------	---

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, month 1, month 3 and month 6

<b>End point values</b>	Placebo	Romosozumab 70 mg/mL	Romosozumab 90 mg/mL	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	51 <sup>[11]</sup>	115 <sup>[12]</sup>	120 <sup>[13]</sup>	
Units: percent change				
median (inter-quartile range (Q1-Q3))				
Month 1 (n = 51, 111, 116)	2 (-5.797 to 16.129)	96.296 (67.143 to 159.341)	97.435 (69.259 to 126.179)	
Month 3 (n = 48, 110, 115)	-9.601 (-21.503 to 2.922)	23.96 (-1.587 to 46.667)	16.216 (-10.39 to 50)	
Month 6 (n = 45, 102, 110)	-12.5 (-27.5 to 14.286)	-2.885 (-28.07 to 18.421)	-3.604 (-22.222 to 27.273)	

Notes:

[11] - Subjects with values at baseline and at  $\geq 1$  post-baseline visit

[12] - Subjects with values at baseline and at  $\geq 1$  post-baseline visit

[13] - Subjects with values at baseline and at  $\geq 1$  post-baseline visit

### Statistical analyses

No statistical analyses for this end point

---

**Secondary: Percent Change From Baseline in Serum C-Telopeptide (CTX)**

---

End point title | Percent Change From Baseline in Serum C-Telopeptide (CTX)

End point description:

End point type | Secondary

End point timeframe:

Baseline, month 1, month 3 and month 6

---

<b>End point values</b>	Placebo	Romosozumab 70 mg/mL	Romosozumab 90 mg/mL	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	51 <sup>[14]</sup>	115 <sup>[15]</sup>	120 <sup>[16]</sup>	
Units: percent change				
median (inter-quartile range (Q1-Q3))				
Month 1 (n = 51, 111, 117)	0.282 (-16.183 to 12.874)	-23.158 (- 42.943 to - 9.967)	-21.456 (- 35.602 to - 7.246)	
Month 3 (n = 48, 110, 116)	-5.687 (- 20.666 to 15.566)	-11.219 (- 35.206 to 9.484)	-5.473 (- 24.139 to 26.386)	
Month 6 (n = 45, 108, 114)	-8.12 (-26.935 to 10.059)	-25.78 (- 43.573 to - 8.216)	-17.305 (- 37.566 to 6.405)	

Notes:

[14] - Subjects with values at baseline and at  $\geq 1$  post-baseline visit.

[15] - Subjects with values at baseline and at  $\geq 1$  post-baseline visit.

[16] - Subjects with values at baseline and at  $\geq 1$  post-baseline visit.

---

**Statistical analyses**

---

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Adverse events are reported from the first dose of study drug until 90 days after last dose (9 months overall).

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
Dictionary version	17.1

### Reporting groups

Reporting group title	Placebo 70 mg/mL
-----------------------	------------------

Reporting group description:

Participants received matching placebo administered as 3 SC injections of 1.0 mL every month for 6 months.

Reporting group title	Placebo 90 mg/mL
-----------------------	------------------

Reporting group description:

Participants received matching placebo administered as 2 subcutaneous (SC) injections of 1.17 mL every month for 6 months.

Reporting group title	Romosozumab 70 mg/mL
-----------------------	----------------------

Reporting group description:

Participants received 210 mg romosozumab monthly, administered as 3 subcutaneous 1 mL injections of a 70 mg/mL solution, for 6 months

Reporting group title	Romosozumab 90 mg/mL
-----------------------	----------------------

Reporting group description:

Participants received 210 mg romosozumab monthly, administered as 2 subcutaneous 1.17 mL injections of a 90 mg/mL solution, for 6 months.

<b>Serious adverse events</b>	Placebo 70 mg/mL	Placebo 90 mg/mL	Romosozumab 70 mg/mL
Total subjects affected by serious adverse events			
subjects affected / exposed	4 / 26 (15.38%)	2 / 26 (7.69%)	7 / 119 (5.88%)
number of deaths (all causes)	1	0	0
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Adenocarcinoma of colon			
subjects affected / exposed	1 / 26 (3.85%)	0 / 26 (0.00%)	0 / 119 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Basal cell carcinoma			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	0 / 119 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Medullary thyroid cancer			
subjects affected / exposed	1 / 26 (3.85%)	0 / 26 (0.00%)	0 / 119 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Uterine cancer			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	1 / 119 (0.84%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Carbon monoxide poisoning			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	1 / 119 (0.84%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femoral neck fracture			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	1 / 119 (0.84%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Humerus fracture			
subjects affected / exposed	0 / 26 (0.00%)	1 / 26 (3.85%)	0 / 119 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Overdose			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	1 / 119 (0.84%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Patella fracture			
subjects affected / exposed	1 / 26 (3.85%)	0 / 26 (0.00%)	0 / 119 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Arterial rupture			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	0 / 119 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	1 / 119 (0.84%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	1 / 119 (0.84%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Surgical and medical procedures			
Umbilical hernia repair			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	1 / 119 (0.84%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Ischaemic stroke			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	1 / 119 (0.84%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Polyneuropathy			
subjects affected / exposed	0 / 26 (0.00%)	1 / 26 (3.85%)	0 / 119 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Retrograde amnesia			
subjects affected / exposed	1 / 26 (3.85%)	0 / 26 (0.00%)	0 / 119 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Coagulopathy			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	1 / 119 (0.84%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Death			

subjects affected / exposed	1 / 26 (3.85%)	0 / 26 (0.00%)	0 / 119 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
<b>Gastrointestinal disorders</b>			
<b>Abdominal pain</b>			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	1 / 119 (0.84%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Appendicitis noninfective</b>			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	1 / 119 (0.84%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Gastritis</b>			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	1 / 119 (0.84%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Mesenteric artery embolism</b>			
subjects affected / exposed	1 / 26 (3.85%)	0 / 26 (0.00%)	0 / 119 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Endocrine disorders</b>			
<b>Hyperthyroidism</b>			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	0 / 119 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Musculoskeletal and connective tissue disorders</b>			
<b>Spinal deformity</b>			
subjects affected / exposed	0 / 26 (0.00%)	1 / 26 (3.85%)	0 / 119 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Spinal osteoarthritis</b>			
subjects affected / exposed	0 / 26 (0.00%)	1 / 26 (3.85%)	0 / 119 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Vertebral lesion			
subjects affected / exposed	0 / 26 (0.00%)	1 / 26 (3.85%)	0 / 119 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Appendicitis perforated			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	1 / 119 (0.84%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	1 / 119 (0.84%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Romsozumab 90 mg/mL		
Total subjects affected by serious adverse events			
subjects affected / exposed	3 / 123 (2.44%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Adenocarcinoma of colon			
subjects affected / exposed	0 / 123 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Basal cell carcinoma			
subjects affected / exposed	1 / 123 (0.81%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Medullary thyroid cancer			
subjects affected / exposed	0 / 123 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Uterine cancer			

subjects affected / exposed	0 / 123 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Injury, poisoning and procedural complications</b>			
Carbon monoxide poisoning			
subjects affected / exposed	0 / 123 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Femoral neck fracture			
subjects affected / exposed	0 / 123 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Humerus fracture			
subjects affected / exposed	0 / 123 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Overdose			
subjects affected / exposed	0 / 123 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Patella fracture			
subjects affected / exposed	0 / 123 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Vascular disorders</b>			
Arterial rupture			
subjects affected / exposed	1 / 123 (0.81%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Cardiac disorders</b>			
Atrial fibrillation			
subjects affected / exposed	0 / 123 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Cardiac failure			
subjects affected / exposed	0 / 123 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Surgical and medical procedures			
Umbilical hernia repair			
subjects affected / exposed	0 / 123 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Ischaemic stroke			
subjects affected / exposed	0 / 123 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Polyneuropathy			
subjects affected / exposed	0 / 123 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Retrograde amnesia			
subjects affected / exposed	0 / 123 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
Coagulopathy			
subjects affected / exposed	0 / 123 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Death			
subjects affected / exposed	0 / 123 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Abdominal pain			

subjects affected / exposed	0 / 123 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Appendicitis noninfective			
subjects affected / exposed	0 / 123 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastritis			
subjects affected / exposed	0 / 123 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Mesenteric artery embolism			
subjects affected / exposed	0 / 123 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Endocrine disorders			
Hyperthyroidism			
subjects affected / exposed	1 / 123 (0.81%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Spinal deformity			
subjects affected / exposed	0 / 123 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Spinal osteoarthritis			
subjects affected / exposed	0 / 123 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vertebral lesion			
subjects affected / exposed	0 / 123 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Infections and infestations			
Appendicitis perforated			
subjects affected / exposed	0 / 123 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Sepsis			
subjects affected / exposed	0 / 123 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 0 %

<b>Non-serious adverse events</b>	Placebo 70 mg/mL	Placebo 90 mg/mL	Romosozumab 70 mg/mL
Total subjects affected by non-serious adverse events			
subjects affected / exposed	17 / 26 (65.38%)	11 / 26 (42.31%)	62 / 119 (52.10%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Thyroid neoplasm			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	1 / 119 (0.84%)
occurrences (all)	0	0	1
Basal cell carcinoma			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	0 / 119 (0.00%)
occurrences (all)	0	0	0
Vascular disorders			
Arteriosclerosis			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	1 / 119 (0.84%)
occurrences (all)	0	0	1
Hot flush			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	1 / 119 (0.84%)
occurrences (all)	0	0	1
Hypertension			
subjects affected / exposed	1 / 26 (3.85%)	0 / 26 (0.00%)	3 / 119 (2.52%)
occurrences (all)	1	0	3
Hypertensive angiopathy			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	1 / 119 (0.84%)
occurrences (all)	0	0	1
Phlebitis			

subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	0 / 119 (0.00%) 0
Varicose vein subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	0 / 119 (0.00%) 0
Surgical and medical procedures Tooth extraction subjects affected / exposed occurrences (all)	1 / 26 (3.85%) 1	0 / 26 (0.00%) 0	1 / 119 (0.84%) 1
General disorders and administration site conditions Administration site erythema subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	0 / 119 (0.00%) 0
Administration site reaction subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	1 / 119 (0.84%) 1
Asthenia subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	2 / 26 (7.69%) 5	4 / 119 (3.36%) 4
Chest pain subjects affected / exposed occurrences (all)	1 / 26 (3.85%) 1	0 / 26 (0.00%) 0	0 / 119 (0.00%) 0
Cyst subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	0 / 119 (0.00%) 0
Fatigue subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	0 / 119 (0.00%) 0
Generalised oedema subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	0 / 119 (0.00%) 0
Influenza like illness subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	0 / 119 (0.00%) 0
Injection site erythema			

subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	2 / 119 (1.68%) 3
Injection site hypersensitivity subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	1 / 119 (0.84%) 2
Injection site inflammation subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	1 / 119 (0.84%) 1
Injection site pain subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	7 / 119 (5.88%) 16
Injection site swelling subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	0 / 119 (0.00%) 0
Local swelling subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	0 / 119 (0.00%) 0
Malaise subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	0 / 119 (0.00%) 0
Polyp subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	1 / 119 (0.84%) 1
Pyrexia subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	1 / 119 (0.84%) 1
Immune system disorders			
Drug hypersensitivity subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	0 / 119 (0.00%) 0
Hypersensitivity subjects affected / exposed occurrences (all)	1 / 26 (3.85%) 1	0 / 26 (0.00%) 0	0 / 119 (0.00%) 0
Seasonal allergy subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	1 / 119 (0.84%) 1

Reproductive system and breast disorders			
Breast mass			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	1 / 119 (0.84%)
occurrences (all)	0	0	1
Breast swelling			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	1 / 119 (0.84%)
occurrences (all)	0	0	1
Respiratory, thoracic and mediastinal disorders			
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	1 / 119 (0.84%)
occurrences (all)	0	0	1
Cough			
subjects affected / exposed	0 / 26 (0.00%)	1 / 26 (3.85%)	1 / 119 (0.84%)
occurrences (all)	0	2	1
Emphysema			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	1 / 119 (0.84%)
occurrences (all)	0	0	1
Respiratory tract congestion			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	0 / 119 (0.00%)
occurrences (all)	0	0	0
Rhinitis allergic			
subjects affected / exposed	0 / 26 (0.00%)	1 / 26 (3.85%)	0 / 119 (0.00%)
occurrences (all)	0	1	0
Sinus congestion			
subjects affected / exposed	1 / 26 (3.85%)	0 / 26 (0.00%)	0 / 119 (0.00%)
occurrences (all)	1	0	0
Psychiatric disorders			
Depression			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	0 / 119 (0.00%)
occurrences (all)	0	0	0
Neurosis			
subjects affected / exposed	0 / 26 (0.00%)	1 / 26 (3.85%)	0 / 119 (0.00%)
occurrences (all)	0	1	0
Investigations			

Blood glucose abnormal subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	0 / 119 (0.00%) 0
Blood potassium increased subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	0 / 119 (0.00%) 0
Blood thyroid stimulating hormone decreased subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	0 / 119 (0.00%) 0
Smear cervix abnormal subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	1 / 119 (0.84%) 1
Thyroid gland scan abnormal subjects affected / exposed occurrences (all)	1 / 26 (3.85%) 1	0 / 26 (0.00%) 0	0 / 119 (0.00%) 0
Thyroxine increased subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	0 / 119 (0.00%) 0
Tri-iodothyronine free increased subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	0 / 119 (0.00%) 0
Weight increased subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	1 / 119 (0.84%) 1
Ultrasound thyroid abnormal subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	0 / 119 (0.00%) 0
Injury, poisoning and procedural complications			
Fall subjects affected / exposed occurrences (all)	2 / 26 (7.69%) 2	0 / 26 (0.00%) 0	2 / 119 (1.68%) 2
Contusion subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	3 / 119 (2.52%) 6
Forearm fracture			

subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	1 / 119 (0.84%)
occurrences (all)	0	0	1
Foot fracture			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	0 / 119 (0.00%)
occurrences (all)	0	0	0
Hand fracture			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	0 / 119 (0.00%)
occurrences (all)	0	0	0
Head injury			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	1 / 119 (0.84%)
occurrences (all)	0	0	1
Ligament injury			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	1 / 119 (0.84%)
occurrences (all)	0	0	1
Ligament sprain			
subjects affected / exposed	1 / 26 (3.85%)	0 / 26 (0.00%)	1 / 119 (0.84%)
occurrences (all)	1	0	1
Meniscus injury			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	1 / 119 (0.84%)
occurrences (all)	0	0	1
Neck injury			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	1 / 119 (0.84%)
occurrences (all)	0	0	2
Patella fracture			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	1 / 119 (0.84%)
occurrences (all)	0	0	1
Procedural pain			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	1 / 119 (0.84%)
occurrences (all)	0	0	1
Radius fracture			
subjects affected / exposed	1 / 26 (3.85%)	0 / 26 (0.00%)	1 / 119 (0.84%)
occurrences (all)	1	0	1
Spinal fracture			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	0 / 119 (0.00%)
occurrences (all)	0	0	0
Tooth fracture			

subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	1 / 119 (0.84%) 1
Cardiac disorders			
Arrhythmia			
subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	2 / 119 (1.68%) 2
Arrhythmia supraventricular			
subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	0 / 119 (0.00%) 0
Mitral valve incompetence			
subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	0 / 119 (0.00%) 0
Atrial fibrillation			
subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	1 / 119 (0.84%) 1
Palpitations			
subjects affected / exposed occurrences (all)	1 / 26 (3.85%) 1	0 / 26 (0.00%) 0	1 / 119 (0.84%) 1
Tricuspid valve incompetence			
subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	1 / 119 (0.84%) 1
Ventricular arrhythmia			
subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	1 / 119 (0.84%) 1
Nervous system disorders			
Balance disorder			
subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	0 / 119 (0.00%) 0
Cerebrovascular disorder			
subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	1 / 26 (3.85%) 1	1 / 119 (0.84%) 1
Cerebrovascular insufficiency			
subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	0 / 119 (0.00%) 0
Dizziness			

subjects affected / exposed occurrences (all)	1 / 26 (3.85%) 1	1 / 26 (3.85%) 1	3 / 119 (2.52%) 3
Headache subjects affected / exposed occurrences (all)	3 / 26 (11.54%) 3	0 / 26 (0.00%) 0	2 / 119 (1.68%) 2
Hypoaesthesia subjects affected / exposed occurrences (all)	1 / 26 (3.85%) 1	0 / 26 (0.00%) 0	0 / 119 (0.00%) 0
Paraesthesia subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	0 / 119 (0.00%) 0
Migraine subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	1 / 26 (3.85%) 1	0 / 119 (0.00%) 0
Sciatica subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	0 / 119 (0.00%) 0
Tremor subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	1 / 119 (0.84%) 1
Vertebrobasilar insufficiency subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	1 / 119 (0.84%) 1
Blood and lymphatic system disorders			
Anaemia subjects affected / exposed occurrences (all)	1 / 26 (3.85%) 1	0 / 26 (0.00%) 0	0 / 119 (0.00%) 0
Leukopenia subjects affected / exposed occurrences (all)	1 / 26 (3.85%) 1	0 / 26 (0.00%) 0	0 / 119 (0.00%) 0
Lymphadenopathy subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	1 / 119 (0.84%) 1
Ear and labyrinth disorders Ear discomfort			

subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	0 / 119 (0.00%) 0
Ear disorder subjects affected / exposed occurrences (all)	1 / 26 (3.85%) 2	0 / 26 (0.00%) 0	0 / 119 (0.00%) 0
Tinnitus subjects affected / exposed occurrences (all)	1 / 26 (3.85%) 2	0 / 26 (0.00%) 0	0 / 119 (0.00%) 0
Vertigo subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	1 / 119 (0.84%) 2
Eye disorders Cataract subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	1 / 119 (0.84%) 1
Gastrointestinal disorders Abdominal distension subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	1 / 119 (0.84%) 1
Abdominal pain subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	1 / 26 (3.85%) 1	1 / 119 (0.84%) 2
Abdominal pain upper subjects affected / exposed occurrences (all)	1 / 26 (3.85%) 1	0 / 26 (0.00%) 0	2 / 119 (1.68%) 2
Aphthous stomatitis subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	1 / 119 (0.84%) 1
Chronic gastritis subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	0 / 119 (0.00%) 0
Constipation subjects affected / exposed occurrences (all)	1 / 26 (3.85%) 1	0 / 26 (0.00%) 0	1 / 119 (0.84%) 1
Diarrhoea			

subjects affected / exposed	0 / 26 (0.00%)	1 / 26 (3.85%)	3 / 119 (2.52%)
occurrences (all)	0	1	3
Diverticulum intestinal			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	1 / 119 (0.84%)
occurrences (all)	0	0	1
Dyspepsia			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	1 / 119 (0.84%)
occurrences (all)	0	0	1
Erosive oesophagitis			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	0 / 119 (0.00%)
occurrences (all)	0	0	0
Faeces discoloured			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	0 / 119 (0.00%)
occurrences (all)	0	0	0
Gastric ulcer			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	1 / 119 (0.84%)
occurrences (all)	0	0	1
Gastritis			
subjects affected / exposed	0 / 26 (0.00%)	1 / 26 (3.85%)	1 / 119 (0.84%)
occurrences (all)	0	1	1
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	2 / 119 (1.68%)
occurrences (all)	0	0	2
Gingival swelling			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	0 / 119 (0.00%)
occurrences (all)	0	0	0
Haemorrhoidal haemorrhage			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	1 / 119 (0.84%)
occurrences (all)	0	0	1
Haemorrhoids			
subjects affected / exposed	1 / 26 (3.85%)	0 / 26 (0.00%)	0 / 119 (0.00%)
occurrences (all)	1	0	0
Inguinal hernia			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	0 / 119 (0.00%)
occurrences (all)	0	0	0
Irritable bowel syndrome			

subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	0 / 119 (0.00%)
occurrences (all)	0	0	0
Large intestine polyp			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	2 / 119 (1.68%)
occurrences (all)	0	0	2
Nausea			
subjects affected / exposed	1 / 26 (3.85%)	0 / 26 (0.00%)	2 / 119 (1.68%)
occurrences (all)	1	0	2
Pancreatitis chronic			
subjects affected / exposed	0 / 26 (0.00%)	1 / 26 (3.85%)	0 / 119 (0.00%)
occurrences (all)	0	1	0
Peptic ulcer			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	0 / 119 (0.00%)
occurrences (all)	0	0	0
Periodontal disease			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	0 / 119 (0.00%)
occurrences (all)	0	0	0
Proctitis			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	0 / 119 (0.00%)
occurrences (all)	0	0	0
Salivary gland calculus			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	1 / 119 (0.84%)
occurrences (all)	0	0	1
Toothache			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	0 / 119 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	1 / 119 (0.84%)
occurrences (all)	0	0	1
Hepatobiliary disorders			
Cholelithiasis			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	1 / 119 (0.84%)
occurrences (all)	0	0	1
Hepatic steatosis			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	0 / 119 (0.00%)
occurrences (all)	0	0	0

Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	1 / 119 (0.84%)
occurrences (all)	0	0	1
Angioedema			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	0 / 119 (0.00%)
occurrences (all)	0	0	0
Dermatitis allergic			
subjects affected / exposed	0 / 26 (0.00%)	1 / 26 (3.85%)	1 / 119 (0.84%)
occurrences (all)	0	1	1
Eczema			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	0 / 119 (0.00%)
occurrences (all)	0	0	0
Erythema			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	0 / 119 (0.00%)
occurrences (all)	0	0	0
Hyperhidrosis			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	1 / 119 (0.84%)
occurrences (all)	0	0	1
Pruritus			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	0 / 119 (0.00%)
occurrences (all)	0	0	0
Pruritus generalised			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	0 / 119 (0.00%)
occurrences (all)	0	0	0
Rash			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	0 / 119 (0.00%)
occurrences (all)	0	0	0
Rash macular			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	0 / 119 (0.00%)
occurrences (all)	0	0	0
Rash pruritic			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	0 / 119 (0.00%)
occurrences (all)	0	0	0
Skin lesion			

subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	0 / 119 (0.00%) 0
Urticaria subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	1 / 26 (3.85%) 1	0 / 119 (0.00%) 0
Renal and urinary disorders			
Dysuria subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	0 / 119 (0.00%) 0
Nephrolithiasis subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	2 / 119 (1.68%) 2
Renal colic subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	0 / 119 (0.00%) 0
Renal cyst subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	0 / 119 (0.00%) 0
Renal pain subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	1 / 26 (3.85%) 2	0 / 119 (0.00%) 0
Urinary tract inflammation subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	1 / 119 (0.84%) 1
Endocrine disorders			
Hyperthyroidism subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	0 / 119 (0.00%) 0
Hypothyroidism subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	2 / 119 (1.68%) 2
Thyroiditis subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	1 / 119 (0.84%) 1
Musculoskeletal and connective tissue disorders			

Back pain			
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)	1 / 119 (0.84%)
occurrences (all)	1	1	1
Arthralgia			
subjects affected / exposed	0 / 26 (0.00%)	1 / 26 (3.85%)	4 / 119 (3.36%)
occurrences (all)	0	2	4
Bone pain			
subjects affected / exposed	0 / 26 (0.00%)	2 / 26 (7.69%)	2 / 119 (1.68%)
occurrences (all)	0	2	2
Exostosis			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	1 / 119 (0.84%)
occurrences (all)	0	0	1
Intervertebral disc disorder			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	0 / 119 (0.00%)
occurrences (all)	0	0	0
Joint stiffness			
subjects affected / exposed	0 / 26 (0.00%)	1 / 26 (3.85%)	0 / 119 (0.00%)
occurrences (all)	0	1	0
Lordosis			
subjects affected / exposed	0 / 26 (0.00%)	1 / 26 (3.85%)	0 / 119 (0.00%)
occurrences (all)	0	1	0
Muscle contracture			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	0 / 119 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal pain			
subjects affected / exposed	1 / 26 (3.85%)	0 / 26 (0.00%)	1 / 119 (0.84%)
occurrences (all)	1	0	1
Muscular weakness			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	0 / 119 (0.00%)
occurrences (all)	0	0	0
Myalgia			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	3 / 119 (2.52%)
occurrences (all)	0	0	3
Osteoarthritis			
subjects affected / exposed	0 / 26 (0.00%)	1 / 26 (3.85%)	2 / 119 (1.68%)
occurrences (all)	0	1	2

Pain in extremity subjects affected / exposed occurrences (all)	1 / 26 (3.85%) 1	0 / 26 (0.00%) 0	2 / 119 (1.68%) 3
Spinal deformity subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	0 / 119 (0.00%) 0
Spinal pain subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	0 / 119 (0.00%) 0
Spinal osteoarthritis subjects affected / exposed occurrences (all)	1 / 26 (3.85%) 1	0 / 26 (0.00%) 0	4 / 119 (3.36%) 4
<b>Infections and infestations</b>			
Bronchitis subjects affected / exposed occurrences (all)	1 / 26 (3.85%) 1	0 / 26 (0.00%) 0	2 / 119 (1.68%) 2
Ear infection bacterial subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	1 / 119 (0.84%) 1
Ear infection viral subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	1 / 119 (0.84%) 1
Gastroenteritis viral subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	1 / 119 (0.84%) 1
Genitourinary chlamydia infection subjects affected / exposed occurrences (all)	1 / 26 (3.85%) 1	0 / 26 (0.00%) 0	0 / 119 (0.00%) 0
Gingivitis subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	0 / 119 (0.00%) 0
Helicobacter infection subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	0 / 119 (0.00%) 0
Herpes zoster			

subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	1 / 119 (0.84%)
occurrences (all)	0	0	1
Infection			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	1 / 119 (0.84%)
occurrences (all)	0	0	1
Influenza			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	1 / 119 (0.84%)
occurrences (all)	0	0	1
Nasopharyngitis			
subjects affected / exposed	3 / 26 (11.54%)	0 / 26 (0.00%)	9 / 119 (7.56%)
occurrences (all)	4	0	10
Laryngitis			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	1 / 119 (0.84%)
occurrences (all)	0	0	1
Onychomycosis			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	0 / 119 (0.00%)
occurrences (all)	0	0	0
Oral herpes			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	0 / 119 (0.00%)
occurrences (all)	0	0	0
Pharyngitis			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	0 / 119 (0.00%)
occurrences (all)	0	0	0
Pharyngitis bacterial			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	1 / 119 (0.84%)
occurrences (all)	0	0	1
Pneumonia			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	1 / 119 (0.84%)
occurrences (all)	0	0	1
Pneumonia bacterial			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	1 / 119 (0.84%)
occurrences (all)	0	0	1
Pulpitis dental			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	0 / 119 (0.00%)
occurrences (all)	0	0	0
Respiratory tract infection			

subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	0 / 119 (0.00%) 0
Respiratory tract infection viral subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	1 / 119 (0.84%) 1
Rhinitis subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	1 / 26 (3.85%) 1	0 / 119 (0.00%) 0
Sinusitis subjects affected / exposed occurrences (all)	1 / 26 (3.85%) 1	0 / 26 (0.00%) 0	0 / 119 (0.00%) 0
Tonsillitis subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	1 / 119 (0.84%) 1
Upper respiratory tract infection subjects affected / exposed occurrences (all)	1 / 26 (3.85%) 1	2 / 26 (7.69%) 2	1 / 119 (0.84%) 1
Upper respiratory tract infection bacterial subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	1 / 119 (0.84%) 1
Urinary tract infection subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	1 / 26 (3.85%) 2	1 / 119 (0.84%) 2
Urinary tract infection bacterial subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	1 / 119 (0.84%) 1
Vaginal infection subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	0 / 119 (0.00%) 0
Viral upper respiratory tract infection subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	0 / 26 (0.00%) 0	2 / 119 (1.68%) 2
Metabolism and nutrition disorders Hypercholesterolaemia			

subjects affected / exposed	1 / 26 (3.85%)	0 / 26 (0.00%)	0 / 119 (0.00%)
occurrences (all)	1	0	0
<b>Hyperlipidaemia</b>			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	1 / 119 (0.84%)
occurrences (all)	0	0	1
<b>Increased appetite</b>			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	1 / 119 (0.84%)
occurrences (all)	0	0	1
<b>Obesity</b>			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	0 / 119 (0.00%)
occurrences (all)	0	0	0
<b>Type 2 diabetes mellitus</b>			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	1 / 119 (0.84%)
occurrences (all)	0	0	1

<b>Non-serious adverse events</b>	Romosozumab 90 mg/mL		
<b>Total subjects affected by non-serious adverse events</b>			
subjects affected / exposed	71 / 123 (57.72%)		
<b>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</b>			
<b>Thyroid neoplasm</b>			
subjects affected / exposed	1 / 123 (0.81%)		
occurrences (all)	2		
<b>Basal cell carcinoma</b>			
subjects affected / exposed	2 / 123 (1.63%)		
occurrences (all)	2		
<b>Vascular disorders</b>			
<b>Arteriosclerosis</b>			
subjects affected / exposed	0 / 123 (0.00%)		
occurrences (all)	0		
<b>Hot flush</b>			
subjects affected / exposed	0 / 123 (0.00%)		
occurrences (all)	0		
<b>Hypertension</b>			
subjects affected / exposed	3 / 123 (2.44%)		
occurrences (all)	3		
<b>Hypertensive angiopathy</b>			

subjects affected / exposed occurrences (all)	0 / 123 (0.00%) 0		
Phlebitis subjects affected / exposed occurrences (all)	1 / 123 (0.81%) 2		
Varicose vein subjects affected / exposed occurrences (all)	1 / 123 (0.81%) 1		
Surgical and medical procedures Tooth extraction subjects affected / exposed occurrences (all)	0 / 123 (0.00%) 0		
General disorders and administration site conditions			
Administration site erythema subjects affected / exposed occurrences (all)	2 / 123 (1.63%) 4		
Administration site reaction subjects affected / exposed occurrences (all)	0 / 123 (0.00%) 0		
Asthenia subjects affected / exposed occurrences (all)	4 / 123 (3.25%) 5		
Chest pain subjects affected / exposed occurrences (all)	0 / 123 (0.00%) 0		
Cyst subjects affected / exposed occurrences (all)	1 / 123 (0.81%) 1		
Fatigue subjects affected / exposed occurrences (all)	1 / 123 (0.81%) 1		
Generalised oedema subjects affected / exposed occurrences (all)	1 / 123 (0.81%) 1		
Influenza like illness			

subjects affected / exposed occurrences (all)	1 / 123 (0.81%) 1		
Injection site erythema subjects affected / exposed occurrences (all)	7 / 123 (5.69%) 23		
Injection site hypersensitivity subjects affected / exposed occurrences (all)	2 / 123 (1.63%) 2		
Injection site inflammation subjects affected / exposed occurrences (all)	2 / 123 (1.63%) 2		
Injection site pain subjects affected / exposed occurrences (all)	3 / 123 (2.44%) 15		
Injection site swelling subjects affected / exposed occurrences (all)	4 / 123 (3.25%) 5		
Local swelling subjects affected / exposed occurrences (all)	1 / 123 (0.81%) 1		
Malaise subjects affected / exposed occurrences (all)	1 / 123 (0.81%) 1		
Polyp subjects affected / exposed occurrences (all)	0 / 123 (0.00%) 0		
Pyrexia subjects affected / exposed occurrences (all)	0 / 123 (0.00%) 0		
Immune system disorders Drug hypersensitivity subjects affected / exposed occurrences (all)	1 / 123 (0.81%) 1		
Hypersensitivity subjects affected / exposed occurrences (all)	0 / 123 (0.00%) 0		

Seasonal allergy subjects affected / exposed occurrences (all)	0 / 123 (0.00%) 0		
Reproductive system and breast disorders Breast mass subjects affected / exposed occurrences (all)  Breast swelling subjects affected / exposed occurrences (all)	0 / 123 (0.00%) 0  0 / 123 (0.00%) 0		
Respiratory, thoracic and mediastinal disorders Chronic obstructive pulmonary disease subjects affected / exposed occurrences (all)  Cough subjects affected / exposed occurrences (all)  Emphysema subjects affected / exposed occurrences (all)  Respiratory tract congestion subjects affected / exposed occurrences (all)  Rhinitis allergic subjects affected / exposed occurrences (all)  Sinus congestion subjects affected / exposed occurrences (all)	1 / 123 (0.81%) 1  1 / 123 (0.81%) 1  0 / 123 (0.00%) 0  1 / 123 (0.81%) 1  1 / 123 (0.81%) 1  0 / 123 (0.00%) 0		
Psychiatric disorders Depression subjects affected / exposed occurrences (all)  Neurosis	1 / 123 (0.81%) 1		

subjects affected / exposed occurrences (all)	0 / 123 (0.00%) 0		
Investigations			
Blood glucose abnormal subjects affected / exposed occurrences (all)	1 / 123 (0.81%) 1		
Blood potassium increased subjects affected / exposed occurrences (all)	1 / 123 (0.81%) 1		
Blood thyroid stimulating hormone decreased subjects affected / exposed occurrences (all)	1 / 123 (0.81%) 1		
Smear cervix abnormal subjects affected / exposed occurrences (all)	0 / 123 (0.00%) 0		
Thyroid gland scan abnormal subjects affected / exposed occurrences (all)	0 / 123 (0.00%) 0		
Thyroxine increased subjects affected / exposed occurrences (all)	1 / 123 (0.81%) 1		
Tri-iodothyronine free increased subjects affected / exposed occurrences (all)	1 / 123 (0.81%) 1		
Weight increased subjects affected / exposed occurrences (all)	0 / 123 (0.00%) 0		
Ultrasound thyroid abnormal subjects affected / exposed occurrences (all)	1 / 123 (0.81%) 1		
Injury, poisoning and procedural complications			
Fall subjects affected / exposed occurrences (all)	2 / 123 (1.63%) 4		
Contusion			

subjects affected / exposed	3 / 123 (2.44%)		
occurrences (all)	6		
Forearm fracture			
subjects affected / exposed	0 / 123 (0.00%)		
occurrences (all)	0		
Foot fracture			
subjects affected / exposed	1 / 123 (0.81%)		
occurrences (all)	1		
Hand fracture			
subjects affected / exposed	1 / 123 (0.81%)		
occurrences (all)	1		
Head injury			
subjects affected / exposed	0 / 123 (0.00%)		
occurrences (all)	0		
Ligament injury			
subjects affected / exposed	0 / 123 (0.00%)		
occurrences (all)	0		
Ligament sprain			
subjects affected / exposed	2 / 123 (1.63%)		
occurrences (all)	2		
Meniscus injury			
subjects affected / exposed	0 / 123 (0.00%)		
occurrences (all)	0		
Neck injury			
subjects affected / exposed	0 / 123 (0.00%)		
occurrences (all)	0		
Patella fracture			
subjects affected / exposed	0 / 123 (0.00%)		
occurrences (all)	0		
Procedural pain			
subjects affected / exposed	0 / 123 (0.00%)		
occurrences (all)	0		
Radius fracture			
subjects affected / exposed	1 / 123 (0.81%)		
occurrences (all)	1		
Spinal fracture			

subjects affected / exposed occurrences (all)	1 / 123 (0.81%) 1		
Tooth fracture subjects affected / exposed occurrences (all)	0 / 123 (0.00%) 0		
Cardiac disorders			
Arrhythmia subjects affected / exposed occurrences (all)	0 / 123 (0.00%) 0		
Arrhythmia supraventricular subjects affected / exposed occurrences (all)	1 / 123 (0.81%) 1		
Mitral valve incompetence subjects affected / exposed occurrences (all)	1 / 123 (0.81%) 1		
Atrial fibrillation subjects affected / exposed occurrences (all)	0 / 123 (0.00%) 0		
Palpitations subjects affected / exposed occurrences (all)	0 / 123 (0.00%) 0		
Tricuspid valve incompetence subjects affected / exposed occurrences (all)	1 / 123 (0.81%) 1		
Ventricular arrhythmia subjects affected / exposed occurrences (all)	0 / 123 (0.00%) 0		
Nervous system disorders			
Balance disorder subjects affected / exposed occurrences (all)	1 / 123 (0.81%) 1		
Cerebrovascular disorder subjects affected / exposed occurrences (all)	0 / 123 (0.00%) 0		
Cerebrovascular insufficiency			

subjects affected / exposed occurrences (all)	1 / 123 (0.81%) 1		
Dizziness subjects affected / exposed occurrences (all)	1 / 123 (0.81%) 1		
Headache subjects affected / exposed occurrences (all)	2 / 123 (1.63%) 2		
Hypoaesthesia subjects affected / exposed occurrences (all)	1 / 123 (0.81%) 1		
Paraesthesia subjects affected / exposed occurrences (all)	1 / 123 (0.81%) 1		
Migraine subjects affected / exposed occurrences (all)	0 / 123 (0.00%) 0		
Sciatica subjects affected / exposed occurrences (all)	3 / 123 (2.44%) 3		
Tremor subjects affected / exposed occurrences (all)	0 / 123 (0.00%) 0		
Vertebrobasilar insufficiency subjects affected / exposed occurrences (all)	0 / 123 (0.00%) 0		
<b>Blood and lymphatic system disorders</b>			
Anaemia subjects affected / exposed occurrences (all)	0 / 123 (0.00%) 0		
Leukopenia subjects affected / exposed occurrences (all)	0 / 123 (0.00%) 0		
Lymphadenopathy subjects affected / exposed occurrences (all)	0 / 123 (0.00%) 0		

<p>Ear and labyrinth disorders</p> <p>Ear discomfort</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 123 (0.81%)</p> <p>1</p>		
<p>Ear disorder</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 123 (0.00%)</p> <p>0</p>		
<p>Tinnitus</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 123 (0.00%)</p> <p>0</p>		
<p>Vertigo</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 123 (0.00%)</p> <p>0</p>		
<p>Eye disorders</p> <p>Cataract</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 123 (0.00%)</p> <p>0</p>		
<p>Gastrointestinal disorders</p> <p>Abdominal distension</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 123 (0.00%)</p> <p>0</p>		
<p>Abdominal pain</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 123 (0.81%)</p> <p>1</p>		
<p>Abdominal pain upper</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 123 (0.81%)</p> <p>1</p>		
<p>Aphthous stomatitis</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 123 (0.00%)</p> <p>0</p>		
<p>Chronic gastritis</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 123 (0.81%)</p> <p>1</p>		
<p>Constipation</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 123 (0.81%)</p> <p>1</p>		
<p>Diarrhoea</p>			

subjects affected / exposed	0 / 123 (0.00%)		
occurrences (all)	0		
Diverticulum intestinal			
subjects affected / exposed	0 / 123 (0.00%)		
occurrences (all)	0		
Dyspepsia			
subjects affected / exposed	0 / 123 (0.00%)		
occurrences (all)	0		
Erosive oesophagitis			
subjects affected / exposed	1 / 123 (0.81%)		
occurrences (all)	1		
Faeces discoloured			
subjects affected / exposed	1 / 123 (0.81%)		
occurrences (all)	1		
Gastric ulcer			
subjects affected / exposed	1 / 123 (0.81%)		
occurrences (all)	1		
Gastritis			
subjects affected / exposed	1 / 123 (0.81%)		
occurrences (all)	1		
Gastrooesophageal reflux disease			
subjects affected / exposed	1 / 123 (0.81%)		
occurrences (all)	1		
Gingival swelling			
subjects affected / exposed	1 / 123 (0.81%)		
occurrences (all)	2		
Haemorrhoidal haemorrhage			
subjects affected / exposed	0 / 123 (0.00%)		
occurrences (all)	0		
Haemorrhoids			
subjects affected / exposed	1 / 123 (0.81%)		
occurrences (all)	1		
Inguinal hernia			
subjects affected / exposed	1 / 123 (0.81%)		
occurrences (all)	1		
Irritable bowel syndrome			

subjects affected / exposed	1 / 123 (0.81%)		
occurrences (all)	1		
Large intestine polyp			
subjects affected / exposed	0 / 123 (0.00%)		
occurrences (all)	0		
Nausea			
subjects affected / exposed	1 / 123 (0.81%)		
occurrences (all)	1		
Pancreatitis chronic			
subjects affected / exposed	0 / 123 (0.00%)		
occurrences (all)	0		
Peptic ulcer			
subjects affected / exposed	1 / 123 (0.81%)		
occurrences (all)	1		
Periodontal disease			
subjects affected / exposed	1 / 123 (0.81%)		
occurrences (all)	1		
Proctitis			
subjects affected / exposed	1 / 123 (0.81%)		
occurrences (all)	1		
Salivary gland calculus			
subjects affected / exposed	0 / 123 (0.00%)		
occurrences (all)	0		
Toothache			
subjects affected / exposed	1 / 123 (0.81%)		
occurrences (all)	1		
Vomiting			
subjects affected / exposed	0 / 123 (0.00%)		
occurrences (all)	0		
Hepatobiliary disorders			
Cholelithiasis			
subjects affected / exposed	0 / 123 (0.00%)		
occurrences (all)	0		
Hepatic steatosis			
subjects affected / exposed	1 / 123 (0.81%)		
occurrences (all)	1		

Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	0 / 123 (0.00%)		
occurrences (all)	0		
Angioedema			
subjects affected / exposed	1 / 123 (0.81%)		
occurrences (all)	1		
Dermatitis allergic			
subjects affected / exposed	3 / 123 (2.44%)		
occurrences (all)	3		
Eczema			
subjects affected / exposed	1 / 123 (0.81%)		
occurrences (all)	12		
Erythema			
subjects affected / exposed	1 / 123 (0.81%)		
occurrences (all)	1		
Hyperhidrosis			
subjects affected / exposed	0 / 123 (0.00%)		
occurrences (all)	0		
Pruritus			
subjects affected / exposed	1 / 123 (0.81%)		
occurrences (all)	10		
Pruritus generalised			
subjects affected / exposed	1 / 123 (0.81%)		
occurrences (all)	2		
Rash			
subjects affected / exposed	1 / 123 (0.81%)		
occurrences (all)	6		
Rash macular			
subjects affected / exposed	1 / 123 (0.81%)		
occurrences (all)	2		
Rash pruritic			
subjects affected / exposed	1 / 123 (0.81%)		
occurrences (all)	1		
Skin lesion			

subjects affected / exposed occurrences (all)	2 / 123 (1.63%) 11		
Urticaria subjects affected / exposed occurrences (all)	0 / 123 (0.00%) 0		
Renal and urinary disorders			
Dysuria subjects affected / exposed occurrences (all)	1 / 123 (0.81%) 1		
Nephrolithiasis subjects affected / exposed occurrences (all)	1 / 123 (0.81%) 1		
Renal colic subjects affected / exposed occurrences (all)	1 / 123 (0.81%) 1		
Renal cyst subjects affected / exposed occurrences (all)	1 / 123 (0.81%) 1		
Renal pain subjects affected / exposed occurrences (all)	0 / 123 (0.00%) 0		
Urinary tract inflammation subjects affected / exposed occurrences (all)	0 / 123 (0.00%) 0		
Endocrine disorders			
Hyperthyroidism subjects affected / exposed occurrences (all)	1 / 123 (0.81%) 1		
Hypothyroidism subjects affected / exposed occurrences (all)	0 / 123 (0.00%) 0		
Thyroiditis subjects affected / exposed occurrences (all)	0 / 123 (0.00%) 0		
Musculoskeletal and connective tissue disorders			

Back pain			
subjects affected / exposed	0 / 123 (0.00%)		
occurrences (all)	0		
Arthralgia			
subjects affected / exposed	6 / 123 (4.88%)		
occurrences (all)	10		
Bone pain			
subjects affected / exposed	2 / 123 (1.63%)		
occurrences (all)	2		
Exostosis			
subjects affected / exposed	1 / 123 (0.81%)		
occurrences (all)	1		
Intervertebral disc disorder			
subjects affected / exposed	1 / 123 (0.81%)		
occurrences (all)	1		
Joint stiffness			
subjects affected / exposed	0 / 123 (0.00%)		
occurrences (all)	0		
Lordosis			
subjects affected / exposed	0 / 123 (0.00%)		
occurrences (all)	0		
Muscle contracture			
subjects affected / exposed	1 / 123 (0.81%)		
occurrences (all)	1		
Musculoskeletal pain			
subjects affected / exposed	2 / 123 (1.63%)		
occurrences (all)	2		
Muscular weakness			
subjects affected / exposed	1 / 123 (0.81%)		
occurrences (all)	1		
Myalgia			
subjects affected / exposed	3 / 123 (2.44%)		
occurrences (all)	4		
Osteoarthritis			
subjects affected / exposed	6 / 123 (4.88%)		
occurrences (all)	6		

Pain in extremity subjects affected / exposed occurrences (all)	4 / 123 (3.25%) 8		
Spinal deformity subjects affected / exposed occurrences (all)	1 / 123 (0.81%) 1		
Spinal pain subjects affected / exposed occurrences (all)	1 / 123 (0.81%) 1		
Spinal osteoarthritis subjects affected / exposed occurrences (all)	2 / 123 (1.63%) 2		
<b>Infections and infestations</b>			
Bronchitis subjects affected / exposed occurrences (all)	3 / 123 (2.44%) 3		
Ear infection bacterial subjects affected / exposed occurrences (all)	0 / 123 (0.00%) 0		
Ear infection viral subjects affected / exposed occurrences (all)	0 / 123 (0.00%) 0		
Gastroenteritis viral subjects affected / exposed occurrences (all)	0 / 123 (0.00%) 0		
Genitourinary chlamydia infection subjects affected / exposed occurrences (all)	0 / 123 (0.00%) 0		
Gingivitis subjects affected / exposed occurrences (all)	1 / 123 (0.81%) 1		
Helicobacter infection subjects affected / exposed occurrences (all)	2 / 123 (1.63%) 2		
Herpes zoster			

subjects affected / exposed	0 / 123 (0.00%)		
occurrences (all)	0		
Infection			
subjects affected / exposed	0 / 123 (0.00%)		
occurrences (all)	0		
Influenza			
subjects affected / exposed	0 / 123 (0.00%)		
occurrences (all)	0		
Nasopharyngitis			
subjects affected / exposed	19 / 123 (15.45%)		
occurrences (all)	21		
Laryngitis			
subjects affected / exposed	0 / 123 (0.00%)		
occurrences (all)	0		
Onychomycosis			
subjects affected / exposed	1 / 123 (0.81%)		
occurrences (all)	1		
Oral herpes			
subjects affected / exposed	1 / 123 (0.81%)		
occurrences (all)	1		
Pharyngitis			
subjects affected / exposed	2 / 123 (1.63%)		
occurrences (all)	2		
Pharyngitis bacterial			
subjects affected / exposed	0 / 123 (0.00%)		
occurrences (all)	0		
Pneumonia			
subjects affected / exposed	0 / 123 (0.00%)		
occurrences (all)	0		
Pneumonia bacterial			
subjects affected / exposed	0 / 123 (0.00%)		
occurrences (all)	0		
Pulpitis dental			
subjects affected / exposed	1 / 123 (0.81%)		
occurrences (all)	1		
Respiratory tract infection			

subjects affected / exposed occurrences (all)	1 / 123 (0.81%) 1		
Respiratory tract infection viral subjects affected / exposed occurrences (all)	0 / 123 (0.00%) 0		
Rhinitis subjects affected / exposed occurrences (all)	1 / 123 (0.81%) 1		
Sinusitis subjects affected / exposed occurrences (all)	4 / 123 (3.25%) 4		
Tonsillitis subjects affected / exposed occurrences (all)	1 / 123 (0.81%) 1		
Upper respiratory tract infection subjects affected / exposed occurrences (all)	2 / 123 (1.63%) 2		
Upper respiratory tract infection bacterial subjects affected / exposed occurrences (all)	0 / 123 (0.00%) 0		
Urinary tract infection subjects affected / exposed occurrences (all)	7 / 123 (5.69%) 7		
Urinary tract infection bacterial subjects affected / exposed occurrences (all)	0 / 123 (0.00%) 0		
Vaginal infection subjects affected / exposed occurrences (all)	1 / 123 (0.81%) 1		
Viral upper respiratory tract infection subjects affected / exposed occurrences (all)	3 / 123 (2.44%) 3		
Metabolism and nutrition disorders Hypercholesterolaemia			

subjects affected / exposed	0 / 123 (0.00%)		
occurrences (all)	0		
Hyperlipidaemia			
subjects affected / exposed	0 / 123 (0.00%)		
occurrences (all)	0		
Increased appetite			
subjects affected / exposed	0 / 123 (0.00%)		
occurrences (all)	0		
Obesity			
subjects affected / exposed	1 / 123 (0.81%)		
occurrences (all)	1		
Type 2 diabetes mellitus			
subjects affected / exposed	0 / 123 (0.00%)		
occurrences (all)	0		

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
16 September 2013	<p>The protocol was amended to include the following changes:</p> <ul style="list-style-type: none"><li>- To include an additional assessment for formation of antiromosozumab antibodies at the month 1 study visit. This additional assessment allowed a more comprehensive characterization of the antiromosozumab antibody response.</li><li>- The eligibility criteria were modified to allow participation of a wider range of subjects. Specifically, the minimal age was lowered from 60 to 55 years and for exclusionary medications, the protocol-mandated off-treatment times were revised. Similarly, the use of vitamin K (and analogs) for the treatment of osteoporosis, and the use of activated vitamin D were added to the on-study excluded treatments list.</li><li>- To account for the imprecision of serum calcium laboratory measurements, retesting of serum calcium was permitted within the screening window if the initial test indicated an elevated level of serum calcium within 1.1x the upper limit of normal set by the central laboratory.</li><li>- It was clarified that if a subject was rescreened for serum 25-hydroxyvitamin D level, they were not required to re consent for the rescreening period.</li><li>- Expectations for serious adverse event reporting were defined for the time after the protocol-mandated reporting period ended.</li><li>- Analysis detail pertaining to the assessment of antiromosozumab antibodies was modified to reflect the statistical analysis plan.</li></ul>

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported